Gilead Sciences, Inc. (NASDAQ:GILD) Stock Holdings Lowered by Sarissa Capital Management LP

Sarissa Capital Management LP trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 65.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 262,080 shares of the biopharmaceutical company's stock after selling 501,253 shares during the period. Gilead Sciences makes up 7.5% of Sarissa Capital Management LP's investment portfolio, making the stock its 5th biggest holding. Sarissa Capital Management LP's holdings in Gilead Sciences were worth $24,208,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. HHM Wealth Advisors LLC grew its stake in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in shares of Gilead Sciences during the 4th quarter valued at $28,000. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences during the 4th quarter valued at $29,000. Crews Bank & Trust bought a new position in shares of Gilead Sciences in the fourth quarter worth $31,000. Finally, Stephens Consulting LLC raised its position in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 260 shares in the last quarter. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 1.3%

GILD traded down $1.39 on Wednesday, hitting $107.72. The company had a trading volume of 7,958,565 shares, compared to its average volume of 7,705,939. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The firm has a market capitalization of $134.00 billion, a P/E ratio of 291.14, a P/E/G ratio of 0.71 and a beta of 0.26. The stock has a fifty day simple moving average of $105.51 and a 200-day simple moving average of $100.02.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. During the same quarter last year, the firm posted ($1.32) earnings per share. The company's revenue for the quarter was down .3% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Oppenheimer reduced their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. BMO Capital Markets boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. Morgan Stanley upped their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Deutsche Bank Aktiengesellschaft raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price target for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Finally, Royal Bank of Canada raised their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a "sector perform" rating in a report on Wednesday, February 12th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $110.55.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 17,929 shares of Gilead Sciences stock in a transaction on Monday, March 10th. The stock was sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the completion of the transaction, the chief financial officer now owns 169,061 shares in the company, valued at approximately $19,977,938.37. The trade was a 9.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 22,929 shares of company stock valued at $2,634,220 over the last quarter. Corporate insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.